Dose Dense Abraxabe for adjuvant therapy of breast cancer – pro
Not much is known about adjuvant dose dense Abraxane. A 2005 study looked at dose dense adjuvant Abraxane, Pilot Study of Dose-Dense Doxorubicin plus Cyclophosphamide Followed by ABI-007 (ABRAXANE) in Patients with Early-Stage Breast Cancer
Preliminary results from this phase II trial showed that dose-dense therapy with doxorubicin (Adriamycin) (A) plus cyclophosphamide (Cytoxan) followed by dose-dense ABRAXANE was well tolerated in patients with early stage breast cancer(1). The open label pilot study was designed to evaluate the toxicity of AC therapy followed by ABRAXANE 260 mg/m2 every two weeks for four cycles each as adjuvant therapy in patients with early stage breast cancer. Another study (http://clinicaltrials.gov/show/NCT00308178) is completed but not yet reported(2). Another pilot study was reported in 2011 (krekow et al). It concluded that adjuvant dose-dense AC followed by 260 mg/m2 dose-dense nab-paclitaxel was feasible in women with early-stage BC, with manageable AEs. Most patients had 1 grade neuropathy 2 months after treatment completion.
1.Nicholas Robert, Lea Krekow, Chris Stokoe, Alicia Clawson, Jose Iglesias, Joyce O’Shaughnessy, Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study, Breast Cancer Research and Treatment
January 2011, Volume 125, Issue 1, pp 115-120
2.nccn, breast Cancer, 2014
3.http://clinicaltrials.gov/show/NCT00308178